Skip to main content

Table 1 Patient baseline characteristics and treatments

From: Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

  All patients, N = 60
Age at diagnosis, mean (SD), years 69.3 (9.4)
White, n (%) 53 (88.3)
Female, n (%) 43 (71.7)
Previous or current smoking history, n (%) 21 (35.0)
New-onset disease, n (%)* 48 (80.0)
Clinical manifestations at disease onset
 Localized headache, n (%) 47 (78.3)
 Scalp tenderness, n (%) 26 (43.3)
 Jaw claudication, n (%) 31 (51.7)
 PMR symptoms, n (%) 32 (53.3)
 Visual manifestations, n (%) 22 (36.7)
 Amaurosis fugax, n (%) 11 (18.3)
 Transient blurry vision, n (%) 18 (30.0)
 Diplopia, n (%) 2 (3.3)
 Permanent vision loss, n (%) 8 (13.3)
  AION, n (%) 7 (11.7)
  CRAO, n (%) 1 (1.7)
 Fever, n (%) 14 (23.3)
 Weight loss, n (%) 20 (33.3)
 ESR, mean (SD), mm/h 72.6 (33.6)
 CRP, mean (SD), mg/L 76.1 (72.7)
 Positive temporal artery biopsy, n/N (%)** 26/51 (51.0)
 Large-vessel vasculitis, n/N (%)** 12/28 (42.9)
Prednisone dose at the time of GCA diagnosis, mean (SD), mg/day 54.0 (19.0)
Duration of prednisone use before TCZ initiation, median (IQR), years 0.6 (0.2–1.4)
Use of other immunosuppressants before TCZ initiation, n (%) 14 (23.3)
Prednisone dose at TCZ initiation, mean (SD), mg/day 30.0 (18.3)
Duration of disease before TCZ initiation , median (IQR), years 0.6 (0.2–1.6)
Received TCZ upon disease onset (new-onset disease), n (%)¥ 15 (25.0)
Received intravenous TCZ, n (%)§ 22 (36.7)
Received subcutaneous TCZ, n (%)§ 44 (73.3)
Duration of TCZ treatment, median (IQR), years 0.5 (0.3–1.4)
  1. AION anterior ischemic optic neuropathy, CRAO central retinal artery occlusion, CRP C-reactive protein, ESR erythrocyte sedimentation rate, GCA giant cell arteritis, IQR interquartile range, MGH Massachusetts General Hospital, PMR polymyalgia rheumatica, TCZ tocilizumab
  2. *At first MGH visit
  3. **Of patients assessed. Large-vessel vasculitis was defined as the presence of circumferential wall thickening, edema, contrast enhancement, and/or 18fluorine-2-deoxy-d-glucose uptake in large arteries identified by cross-sectional imaging including magnetic resonance angiography, computed tomography angiography, or positron emission tomography
  4. Of 59 patients with prednisone use prior to TCZ initiation
  5. Other immunosuppressants included methotrexate, ustekinumab, abatacept, rituximab, leflunomide, tofacitinib, and cyclophosphamide
  6. ¥TCZ started within 10 weeks of GCA diagnosis without preceding disease flare
  7. §Six patients received both intravenous and subcutaneous TCZ